Plasmapp was recognized by the American Animal Association when Covetrus exhibited Plasmapp's sterilization solution (STERLINK) at the world's largest veterinary conference (VMX, Veterinary Meeting & Expo) held in Florida, USA from January 14th to 18th. It was announced that full-scale sales have begun in the hospital market.

▲ Covetrus participating in VMX is introducing Plasmapp’s STERLINK Mini

The VMX Conference is the world's largest veterinary conference held every year in Orlando, Florida, and is attended by more than 15,000 veterinarians, technicians, and other members of the veterinary industry.

Covetrus is a global company that continues to be ranked first in terms of sales channels and sales volume in the U.S. and global animal hospital markets, with annual sales reaching 6 trillion won. Covetrus began selling Plasmapp's sterilizer products to the U.S. animal hospital market by exhibiting them at the VMX participating booth.

Plasmapp signed a mid- to long-term supply contract worth 80 billion won with Covetrus in September of last year, and is preparing to expand the scope of cooperation to the global market, starting with entering the U.S. animal hospital market. After signing the contract, Plasmapp's product promotion strategy and customer response system were established, and as this VMX conference is the first venue to jointly showcase products, it is expected to achieve a large-scale promotional effect and accelerate sales.

Plasmapp's sterilization solution presented at this exhibition is the first non-American sterilizer certified by the U.S. FDA. It is a compact sterilizer that can be used in small and medium-sized clinics, and is the only low-temperature sterilization solution in the U.S. market, creating an exclusive market position in the U.S. market and growing rapidly. is continuing.

Youbong Lim, CEO of Plasmapp, said, “For our cooperation with Covetrus, the U.S. animal hospital market is just the beginning, and we will expand into the global market.” He added, “We are expanding our cooperation with global companies to include ophthalmology, orthopedics, and dentistry.” “We will strengthen our partnerships and increase our growth potential,” he said.

Source: Medical Times ( https://www.medicaltimes.com/Main/News/NewsView.html?ID=1151617&ref=naverpc )